CZ20012373A3 - Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje - Google Patents

Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje Download PDF

Info

Publication number
CZ20012373A3
CZ20012373A3 CZ20012373A CZ20012373A CZ20012373A3 CZ 20012373 A3 CZ20012373 A3 CZ 20012373A3 CZ 20012373 A CZ20012373 A CZ 20012373A CZ 20012373 A CZ20012373 A CZ 20012373A CZ 20012373 A3 CZ20012373 A3 CZ 20012373A3
Authority
CZ
Czechia
Prior art keywords
alkyl
carbon atoms
group
formula
compounds
Prior art date
Application number
CZ20012373A
Other languages
Czech (cs)
English (en)
Inventor
Wilfried Lubisch
Michael Kock
Thomas Höger
Sabine Schult
Roland Grandel
Reinhold MÜLLER
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of CZ20012373A3 publication Critical patent/CZ20012373A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CZ20012373A 1999-09-28 2000-09-15 Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje CZ20012373A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung

Publications (1)

Publication Number Publication Date
CZ20012373A3 true CZ20012373A3 (cs) 2002-05-15

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012373A CZ20012373A3 (cs) 1999-09-28 2000-09-15 Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje

Country Status (17)

Country Link
EP (1) EP1183259A2 (fr)
JP (1) JP2003510328A (fr)
KR (1) KR20010087401A (fr)
CN (1) CN1374961A (fr)
AU (1) AU1271201A (fr)
BG (1) BG105650A (fr)
BR (1) BR0007174A (fr)
CA (1) CA2352194A1 (fr)
CZ (1) CZ20012373A3 (fr)
HK (1) HK1048999A1 (fr)
HU (1) HUP0104917A3 (fr)
IL (1) IL143349A0 (fr)
NO (1) NO20012567L (fr)
PL (1) PL347885A1 (fr)
SK (1) SK8842001A3 (fr)
TR (1) TR200101499T1 (fr)
WO (1) WO2001023390A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20691B (sl) 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002044183A2 (fr) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Composes et leurs utilisations
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE50310378D1 (de) 2002-07-26 2008-10-02 Basf Plant Science Gmbh Neue selektionsverfahren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
WO2005028467A1 (fr) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Composes heteroaromatiques et aromatiques a substitution 3,5-diaminopiperidine antibacteriens
CN102107008B (zh) 2003-12-01 2013-04-03 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000762A (es) 2004-07-22 2007-04-02 Ptc Therapeutics Inc Tienopiridinas para tratamientode hepatitis c.
EP2166100B1 (fr) 2005-03-08 2012-07-18 BASF Plant Science GmbH Séquences introniques facilitant l'expression
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
HUE030800T2 (en) 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
WO2011058367A2 (fr) 2009-11-13 2011-05-19 Astrazeneca Ab Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
CN102686726B (zh) 2009-11-27 2015-12-16 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
BR112012012444A2 (pt) 2009-11-27 2015-09-22 Basf Plant Science Co Gmbh "endonuclease quimérica, polinucleotídeo isolado, cassete de expressão, vetor, organismo não humano, método para fornecer uma endonuclease quimérica, método para recombinação homóloga de polinucleotídeos, método para mutação alvejada de polinucleotídeosa e método para recombinação homóloga ou mutação alvejada"
AU2010325549B2 (en) 2009-11-27 2017-04-20 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (fr) 2017-03-08 2018-09-13 Onxeo Nouveau biomarqueur prédictif de la sensibilité à un traitement du cancer avec une molécule dbait
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2018218025A1 (fr) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Inhibiteurs de parp radiomarqués et fluorescents pour l'imagerie et la radiothérapie
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
BR112021015149A2 (pt) * 2019-02-02 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Análogo de indolo heptamil oxima como inibidor de parp
WO2021018298A1 (fr) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 Composés acyloxime à sept chaînons indolo servant d'inhibiteurs de parp
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US20230331739A1 (en) * 2020-07-31 2023-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (fr) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp
SI20691B (sl) * 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Also Published As

Publication number Publication date
BG105650A (en) 2002-02-28
CN1374961A (zh) 2002-10-16
NO20012567L (no) 2001-06-25
BR0007174A (pt) 2001-09-04
CA2352194A1 (fr) 2001-04-05
TR200101499T1 (tr) 2002-09-23
WO2001023390A2 (fr) 2001-04-05
AU1271201A (en) 2001-04-30
IL143349A0 (en) 2002-04-21
NO20012567D0 (no) 2001-05-25
JP2003510328A (ja) 2003-03-18
HUP0104917A2 (hu) 2002-04-29
SK8842001A3 (en) 2002-01-07
PL347885A1 (en) 2002-04-22
HK1048999A1 (zh) 2003-04-25
EP1183259A2 (fr) 2002-03-06
WO2001023390A3 (fr) 2001-12-27
KR20010087401A (ko) 2001-09-15
HUP0104917A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
CZ20012373A3 (cs) Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje
US7087637B2 (en) Substituted indoles which are PARP inhibitors
US8318720B2 (en) Acrylamide derivatives as Fab I inhibitors
US9029392B2 (en) Quinoline derivatives as kinase inhibitors
US20080261975A1 (en) Tec Kinase Inhibitors
SK286676B6 (sk) Použitie ftalazínových derivátov
PL196367B1 (pl) Podstawione benzimidazole, ich zastosowanie jako inhibitorów PARP oraz środek leczniczy
CZ20011724A3 (cs) Použití derivátu 2-fenylbenzimidazolu a 2-fenylindolu pro výrobu drog
CZ20013775A3 (cs) Derivát benzimidazolu substituovaný cykloalkylovou skupinou, způsob jeho přípravy a jeho pouľití
JP2008156370A (ja) Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
KR20020031602A (ko) 벤조디아제핀 유도체, 그의 제조 방법 및 용도
US10919869B2 (en) Thiazole derivative and applications
AU2002247059B2 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
CZ126899A3 (cs) Deriváty kyseliny piperidinketokarbonové, jejich použití a léčebný přípravek
AU2002211827B2 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US20060183908A1 (en) Heterocyclic compounds, methods of making them and their use in therapy
CA2388729A1 (fr) Derives d'imidazopyridine comme inhibiteurs de phosphodiesterase vii
US7026311B2 (en) Dibenzodiazepine derivatives, their preparation and use
JP2015028010A (ja) フルオレン−アミド化合物およびその医薬用途
KR100345187B1 (ko) 트롬복산a2-개재된질환의예방및치료제
KR101048377B1 (ko) 2,4-비스(트리플루오로에톡시)피리딘 화합물 및 이를함유하는 의약.
MXPA01005199A (en) Azepinoindole derivatives, the production and use thereof
CN116063326A (zh) 作为蛋白激酶调节剂的含氨基大环化合物